DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...

DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...

Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump’s tariffs are ...

DexCom Inc. closed 39.31% below its 52-week high of $132.26, which the company reached on May 17th.

I wore Dexcom’s over-the-counter blood glucose monitor for a month. Here’s how it compares to Lingo and what it’s like to use ...

DexCom Inc. closed 38.36% below its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom jumped over 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices ...